« Flawed patents on hepatitis C drugs latest to be challenged in global push for access | Main | Gilead denied patent for hepatitis C drug sofosbuvir in India »

I-MAK, Indian Health Advocates Appeal Patent Office Reversal on Gilead’s Hepatitis C Drug

Patent and Health Experts Denounce Indian Patent Office’s Sofosbuvir Reversal, Vow to Fight for Public Health and Accountability to the Law

CONTACT: Niketa Kumar, Niketa.Kumar@berlinrosen.com, (646) 200-5289

Anjali Cadambi, Anjali.Cadambi@berlinrosen.com, (503) 984-4020

NEW YORK – To ensure Gilead cannot claim existing public knowledge as its own and help the millions of people around the world with hepatitis C get the medicine they need to survive, the Initiative for Medicines, Access & Knowledge (I-MAK) and the Delhi Network of Positive People (DNP+) filed an appeal today with the Delhi High Court. I-MAK and DNP+ are appealing the Indian patent office’s deeply flawed about-face granting Gilead an unmerited patent for sofosbuvir, the base compound in its hepatitis C drug. Last year, the Indian patent office rejected Gilead’s patent, ruling that the main compound in sofosbuvir was a “molecule with minor changes” and has the “same use in treatment of HCV infection and flavivirus injection” compared with an earlier compound.

“The facts of the case are undeniable: sofosbuvir, the base compound in Gilead’s hepatitis C drugs, was developed with previously published techniques that have been used repeatedly in other antiviral drugs,” said Tahir Amin, co-director of I-MAK. “Despite the growing pressure on India’s patent office from the U.S. trade regime and from Gilead’s manipulative licensing deals, we’re confident that we will win and ensure the Indian patent system stays accountable to the integrity of the law and to the public’s health.”

I-MAK and DNP+ have filed the appeal on the grounds that the Indian patent office’s latest and unfounded decision is contrary to the public interest, fails to assess the full scientific and legal evidence presented and ignores key Indian patent law and judicial precedents. 

As recent news reports have detailed, the Indian patent office and officials at the highest levels of the Indian government are facing heavy pressure from the U.S. and pharmaceutical companies like Gilead to weaken patent laws and policies in favor of corporate interests. Following challenges by I-MAK and its partners, China, Ukraine and Egypt have already rejected Gilead’s sofosbuvir patents. 

“The health and wellbeing of millions in India, and around the globe, depends on the rejection of unmerited patents, which create barriers to treatment and block access to life-saving drugs,” said Loon Gangte of the Delhi Network of Positive People and Regional Co-ordinator of ITPC-South Asia. “This latest decision by the Indian patent office will only deepen the public health crisis, and force millions of patients around the world to continue to pay exorbitantly high prices. Patients everywhere, including those countries with high HCV burden excluded by Gilead’s licenses deserve affordable access to care, so that they can lead healthy lives.”

Despite the company’s rhetoric, Gilead’s licensing deals – in India and other countries – are designed to serve the company and increase profits, not to serve patients and increase access to needed hepatitis C drugs. Like unmerited patents, these schemes manipulate the market, violate patients’ rights and block millions of people from getting life-saving medicines.

The hepatitis C virus, which the World Health Organization has called a “viral time bomb,” affects about 150 million people globally. This month, the Centers for Disease Control and Prevention released new data which found hepatitis C kills more Americans than any other infectious disease.

I-MAK’s successful patent challenges in countries around the world have helped government health programs and patients save hundreds of millions of dollars and get the medicine they need to survive and lead healthy lives.

References (56)

References allow you to track sources for this article, as well as articles that were written in response to this article.

Reader Comments (1)

Thank you for the useful information. You might be interested in NCDIR Previous Papers

June 22, 2017 | Unregistered Commenterkavya

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>